Alzheimers Disease on the Rise in the U.S.:
Every 70 Seconds, Someone Develops This Crippling Illness
Expert Available to Comment on New 2009 Alzheimers Association
Facts and Figures
— Available for Radio Interviews on August 11, 2009 from 7 a.m. 12 p.m. ET —
What: The Alzheimers Association 2009 annual report revealed that there are now an estimated 5.3 million Americans living with Alzheimers disease, and that number is expected to increase by nearly 50 percent by 2030. The report (available at www.alz.org) also states that studies have consistently shown that active medical management of Alzheimers and other Dementias can significantly improve quality of life through all stages of the disease for diagnosed individuals and their caregivers, and notes that this includes the use of available treatment options. Check out www.alv.org and www.atpclinicalresearch.com
A physician and Alzheimers expert on the front lines with patients and caregivers is available for interviews to discuss this new information and put it in context for the general public.
Who: Gustavo Alva, M.D., Associate Professor in the Department of Psychiatry and Human Behavior at the University of California, Irvine (UCI); and Medical Director of ATP Clinical Research. Dr. Alva also serves as a diplomat of the American Board of Psychiatry and Neurology.
When: Dr. Alva is available for interviews on Tuesday, August 11, 2009, to discuss:
The impact of Alzheimers disease on baby boomers, as well as the general population
Signs and symptoms of Alzheimers disease
The importance of diagnosis and available treatment options
Tips for caring for a loved one with Alzheimers disease
Contact: To schedule an interview, contact Jen Reeder, SM Media, 888.541.5551 ext. 2
Alzheimer’s Disease Facts
Every 70 seconds, someone in the U.S. develops Alzheimers disease. By 2050, someone will develop it every 33 seconds.
In 2006, Alzheimers disease was the sixth-leading cause of death in the U.S. with 72,914 reported deaths.
An estimated one in eight persons aged 65 or older (13 percent) have Alzheimers disease and nearly half of those with the disease are 85 or older. By 2050, the number of individuals aged 65 and older with Alzheimers disease is projected to be between 11 million and 16 million, with 60 percent of people being 85 or older.
It is estimated that 10 million of the 78 million U.S. baby boomers who are alive today can expect to develop Alzheimers disease in their remaining lifetime.
More than 40 percent of caregivers of people with Alzheimers and other dementias report that they frequently experience high levels of stress and about one third say they suffer from depression.
This radio media tour is made available by Forest Laboratories, Inc., makers of Namenda (memantine HCl), indicated for the treatment of moderate to severe Alzheimers disease.
Namenda (memantine HCl) is indicated for the treatment of moderate to severe Alzheimers disease. Namenda is contraindicated in patients with known hypersensitivity to memantine HCl or any excipients used in the formulation. The most common adverse events reported with Namenda vs placebo (?5% and higher than placebo) were dizziness, confusion, headache, and constipation. In patients with severe renal impairment, the dosage should be reduced. Please see accompanying full prescribing information for Namenda.
